- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
**Q3 FY2025 Investor Presentation Summary:**
**Financial Highlights:**
MedPlus reported ₹15,614 Cr in revenue, marking an 8.3% year-over-year increase, although down 0.9% quarter-over-quarter. Gross margin improved to ₹3,909 Cr with a margin of 25.0%, reflecting a 290 bps increase year-over-year. Operating EBITDA reached ₹799 Cr, yielding a margin of 5.1%. Notably, operating cash flow surged to ₹1,604 Cr, highlighting strong liquidity with a closing cash balance of ₹4,030 Cr.
**Strategic Initiatives and Growth Drivers:**
The company showcased a robust expansion strategy, adding 60 stores during the quarter to reach a total of 4,612 stores. MedPlus continues its focus on growing existing clusters while entering new ones, leveraging an extensive in-house technology platform for an omni-channel approach.
**Business Developments:**
MedPlus' private label segment saw a rise, which is crucial for enhancing profit margins. The company maintains over 1,200 SKUs in its private label offering, improving product competitiveness.
**Market Position and Competitive Advantage:**
As the second-largest pharmacy retailer in India, MedPlus benefits from a strong store network covering 700+ cities, positioning itself well against online-only and traditional competitors. The cluster-based network enables effective service delivery, including quick, hyperlocal order fulfillment.
**Investor Implications:**
With sustained revenue growth, improving margins, and a strong cash position, MedPlus represents a positive outlook for investors. The expansion of the private label range and enhancing omni-channel services could drive future growth and profitability, making it a stock to watch closely.